SLU-PP-332: A novel compound SLU-PP-332 is a relatively new compound in the pharmaceutical landscape
Progress Photos: Standardized photos (same lighting, angles, clothing) every 2-4 weeks document visual changes that measurements may miss
When NNMT is overactive, it consumes S-adenosylmethionine (SAM) and reduces levels of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme involved in cellular energy production
For histological analysis, the femoral and tibial condyles were fixed in 10% neutral buffered formalin, decalcified with 20% EDTA, embedded in paraffin, and sectioned into 5-m thick frontal slices
[1] Selectivity testing indicated the scaffold did not inhibit related SAM-dependent methyltransferases or NAD+ salvage enzymes
however, dedicated cardiovascular outcome trial (CVOT) data have not yet been published, and cardiovascular benefit has not been demonstrated Phase 3 trials are ongoing